News

Dr. Reddys API team at CPHI Japan 2025

Dr. Reddy’s Wins Big at “Express Pharma Excellence Awards 2025”

Tokyo, April 11, 2025 — Dr. Reddy’s Laboratories’ Active Pharmaceutical Ingredients (API) division made a strong impression at CPHI Japan 2025, held at Tokyo Big Sight from April 9–11. As one of the leading global suppliers of high-quality APIs, the company highlighted its expansive portfolio of over 250 APIs across key therapeutic areas including oncology, cardiovascular, and dermatology. The team, led by Nirav Shah, Vice President and Head of API – North Asia, engaged with partners and stakeholders to discuss sustainable sourcing, regulatory excellence, and early market entry strategies. Dr. Reddy’s also emphasized its commitment to sustainability and ESG leadership, having earned recognition in the Bloomberg Gender-Equality Index and Dow Jones Sustainability Index.

Email us: api@drreddys.com
+91 40 49002253

Contact Us

Please fill in the following form and we'll get back to you shortly.

* I agree and accept the Privacy Policy and Terms of Use of this website.

Email us: api@drreddys.com | +91 40 49002222

Disclaimer

No information on this website, including any reference to any product or service constitutes an offer for sale or be construed as representing an offer for sale. Products protected under valid patents are not offered or supplied for commercial use. However, in certain cases, at Dr. Reddy's sole discretion, and subject to local legal requirement, the research quantities of such products may be offered for the purpose of regulatory submissions under Section 107A of the Indian Patent Act (Bolar exemption), wherever such regulatory exemptions exist. The buyers should make their independent evaluation of the product or service including, patent scenario in their respective markets and will be responsible for all patent related liabilities Dr. Reddy's disclaims all warranties, express or implied, including but not limited to warranties of merchantability, fitness for a particular purpose and non-infringement.